

# Ensign Group, Inc. (ENSG)

Nasdaq; healthcare; SIC 8051, Services-Skilled Nursing Care Facilities; CIK 0001125376

| Ensign Group, Inc.<br>ENSG; healthcare |                                                                                                                                                                                                                                   |
|----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Grade</b>                           | <div> <div>A</div> <div> <div>▼</div> <div>A</div> <div>B</div> <div>C</div> <div>D</div> <div>E</div> </div> </div> <p>strongest fifth of 371 graded peers<br/>percentile 15.9; sampling error 2.5 points; lower is stronger</p> |
| <b>Rank</b>                            | 60 of 371                                                                                                                                                                                                                         |
| <b>Profitability</b>                   | <div> <div>B/C</div> <div> <div></div> <div></div> <div></div> <div></div> <div></div> </div> <div>percentile 41.5</div> </div>                                                                                                   |
| <b>Solvency</b>                        | <div> <div>B</div> <div> <div></div> <div></div> <div></div> <div></div> <div></div> </div> <div>percentile 36.3</div> </div>                                                                                                     |
| <b>Growth and financing</b>            | <div> <div>B</div> <div> <div></div> <div></div> <div></div> <div></div> <div></div> </div> <div>percentile 28.1</div> </div>                                                                                                     |
| <b>Reliability</b>                     | <p>0.94 AUC</p> <p>filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025</p>                                                                                                                        |
| <b>Peer failure rate</b>               | <p>0.52% a year</p> <p>Item 1.03 bankruptcies, same asset band, 2012 to 2025</p>                                                                                                                                                  |
| <b>Size band</b>                       | <p>over \$2.67B assets</p> <p>total assets \$5.5B</p>                                                                                                                                                                             |
| <b>Standard universe</b>               | <p>inside</p> <p>revenue above \$1M and assets above \$10M</p>                                                                                                                                                                    |
| <b>Warnings</b>                        | none active; fortress balance sheet                                                                                                                                                                                               |
| <b>Inputs computable</b>               | 11 of 14                                                                                                                                                                                                                          |
| <b>Graded from</b>                     | <p>filings received through Feb 4, 2026</p> <p>247 days before the rescans; latest periodic filing 10-Q received Jul 27, 2026</p>                                                                                                 |
| <b>Last close</b>                      | <p>\$171.41</p> <p>2026-10-08; market equity \$10.0B</p>                                                                                                                                                                          |
| <b>Price used in grade</b>             | None                                                                                                                                                                                                                              |



## A, the bull

strongest fifth of its sector;  
letters are fifths of the 371  
graded peers

## Share price, twelve months to the rescans


split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: A/B from Mar 21, 2026, A from Aug 21, 2026, A/B from Sep 30, 2026, A from Oct 9, 2026

## Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



## Business, in the company's words

opening of Item 1 of the 10-K received Feb 4, 2026

Founded in 1999, The Ensign Group, Inc. (Ensign) is a holding company with independent subsidiaries that provide skilled nursing, senior living and rehabilitative services, as well as other ancillary businesses (including mobile diagnostics and medical transportation), in 17 states. As part of our investment strategy, we also acquire, lease and own healthcare real estate to service the post-acute care continuum through acquisition and investment opportunities in healthcare properties. For the year ended December 31, 2025, we generated approximately 95.6% of our revenue from our skilled nursing facilities.

## The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

| Input                                               | Percentile, 0 to 100 | Value          | Peer median | Percentile | Peers | Period end                                                                |
|-----------------------------------------------------|----------------------|----------------|-------------|------------|-------|---------------------------------------------------------------------------|
| <b>Profitability, sleeve percentile 41.5</b>        |                      |                |             |            |       |                                                                           |
| Gross profitability                                 |                      | 18.5%          | 32.2%       | 65.5       | 372   | 2025-12-31                                                                |
| Return on invested capital                          |                      | 18.9%          | 9.3%        | 19.2       | 74    | 2025-12-31                                                                |
| Accruals ratio                                      |                      | (4.3%)         | (6.6%)      | 64.2       | 811   | 2025-12-31                                                                |
| Gross margin stability, five years                  |                      | 1.2 pts        | 2.8 pts     | 16.9       | 243   | 2025-12-31                                                                |
| <b>Solvency, sleeve percentile 36.3</b>             |                      |                |             |            |       |                                                                           |
| Twelve-month failure probability                    |                      | 0.03%          | 0.07%       | 19.0       | 248   | 2026-06-30                                                                |
| Altman Z double-prime                               |                      | 2.75           | (0.31)      | 26.4       | 756   | 2025-12-31                                                                |
| Net debt to EBITDA                                  |                      | (0.68x)        | 1.82x       | 17.6       | 75    | 2025-12-31                                                                |
| Interest coverage                                   |                      | not computable | (4.51x)     |            |       | latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31 |
| Current ratio                                       |                      | 1.42x          | 2.96x       | 82.3       | 839   | 2025-12-31                                                                |
| <b>Growth and financing, sleeve percentile 28.1</b> |                      |                |             |            |       |                                                                           |
| Revenue growth, three-year compound                 |                      | 18.5%          | 10.0%       | 33.3       | 415   | 2025-12-31                                                                |
| Free cash flow growth, three-year compound          |                      | not computable | 10.9%       |            |       | latest aligned inputs end 2019-12-31; latest annual assets end 2025-12-31 |
| Reinvestment rate                                   |                      | not computable | 37.1%       |            |       | latest aligned inputs end 2019-12-31; latest annual assets end 2025-12-31 |
| Asset growth, three years                           |                      | 16.5%          | 2.1%        | 24.6       | 704   | 2025-12-31                                                                |
| Net share issuance, one year                        |                      | 1.1%           | 2.5%        | 26.2       | 634   | 2026-01-30                                                                |


## Warnings

1 of 7 checks triggered; none of them enters the letter

| Check                  | Measured                                                 |
|------------------------|----------------------------------------------------------|
| Fortress balance sheet | cash minus debt is 359,529,000 USD; Altman Z is not used |

## Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

| Rank | Company | Percentile | Letter | Warnings |
|------|---------|------------|--------|----------|
|------|---------|------------|--------|----------|

|    |                                       |      |                             |
|----|---------------------------------------|------|-----------------------------|
| 55 | Lantheus Holdings, Inc. (LNTH)        | 14.6 | A                           |
| 56 | Harrow, Inc. (HROW)                   | 14.9 | A late filer                |
| 57 | Edwards Lifesciences Corp. (EW)       | 15.1 | A                           |
| 58 | Vertex Pharmaceuticals Inc. MA (VRTX) | 15.4 | A                           |
| 59 | CareDx, Inc. (CDNA)                   | 15.7 | A                           |
| 60 | Ensign Group, Inc. (ENSG) <           | 15.9 | A fortress<br>balance sheet |
| 61 | RxSight, Inc. (RXST)                  | 16.2 | A fortress<br>balance sheet |
| 62 | Definium Therapeutics, Inc. (DFTX)    | 16.5 | A dilution                  |
| 63 | Natures Sunshine Products Inc. (NATR) | 16.8 | A fortress<br>balance sheet |
| 64 | Alnylam Pharmaceuticals, Inc. (ALNY)  | 17.0 | A                           |
| 65 | Aurinia Pharmaceuticals Inc. (AUPH)   | 17.3 | A                           |

## What the price implies

at the 2026-10-08 close; none enters the grade

| Measure                                                 | Value   | Peer median | Percentile |
|---------------------------------------------------------|---------|-------------|------------|
| Twelve-month price change, skipping the latest month    | (0.2%)  | 8.0%        | 46         |
| Distance from 52-week high                              | (20.5%) | (31.4%)     | 65         |
| EBIT to enterprise value                                | 4.3%    | (1.5%)      | 73         |
| Free cash flow yield                                    | 1.2%    | (1.0%)      | 61         |
| Book value to price                                     | 0.24    | 0.28        | 47         |
| Sales to price                                          | 0.50    | 0.31        | 67         |
| Composite equity issuance, five years                   | 5.2%    | 20.3%       | 33         |
| Relative strength against the sector, log excess return | (0.21)  | (0.14)      | 46         |

## Diagnostics

not in the grade

| Measure                                                | Value                           |
|--------------------------------------------------------|---------------------------------|
| <b>Piotroski F-score 6 of 9, period end 2025-12-31</b> |                                 |
| Return on assets above zero                            | pass                            |
| Operating cash flow above zero                         | pass                            |
| Return on assets improved                              | pass                            |
| Operating cash flow exceeds net income                 | pass                            |
| Long-term leverage fell                                | pass                            |
| Current ratio improved                                 | fail                            |
| No new shares issued                                   | fail                            |
| Gross margin improved                                  | fail                            |
| Asset turnover improved                                | pass                            |
| <b>Cash, filings, liquidity</b>                        |                                 |
| Cash and equivalents                                   | \$262.3M                        |
| Operating cash flow, four quarters                     | \$608.4M                        |
| Months of runway                                       | not finite                      |
| Days since last periodic filing                        | 74 (10-Q received Jul 27, 2026) |
| Median daily dollar volume, 63 sessions                | \$60.2M                         |

## Sources

each row links to the filing index on sec.gov

| # | Concept          | XBRL tag                                                            | Value    | Period end | Received   | Form | Accession            |
|---|------------------|---------------------------------------------------------------------|----------|------------|------------|------|----------------------|
| 1 | revenue          | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax         | \$5.0B   | 2025-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 2 | cost of revenue  | us-gaap:CostOfGoodsAndServicesSold                                  | \$4.0B   | 2025-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 3 | assets           | us-gaap:Assets                                                      | \$5.5B   | 2025-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 4 | operating income | us-gaap:OperatingIncomeLoss                                         | \$425.3M | 2025-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 5 | pretax income    | us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord | \$455.6M | 2025-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 6 | income tax       | us-gaap:IncomeTaxExpenseBenefit                                     | \$111.4M | 2025-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 7 | total debt       | us-gaap:LongTermDebt                                                | \$144.4M | 2025-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |

|    |                           |                                                                                              |            |            |            |      |                      |
|----|---------------------------|----------------------------------------------------------------------------------------------|------------|------------|------------|------|----------------------|
| 8  | book equity               | us-gaap:StockholdersEquity                                                                   | \$2.2B     | 2025-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 9  | cash                      | us-gaap:CashAndCashEquivalentsAtCarryingValue                                                | \$503.9M   | 2025-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 10 | total debt                | us-gaap:LongTermDebt                                                                         | \$148.4M   | 2024-12-31 | 2025-02-05 | 10-K | 0001125376-25-000021 |
| 11 | book equity               | us-gaap:StockholdersEquity                                                                   | \$1.8B     | 2024-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 12 | cash                      | us-gaap:CashAndCashEquivalentsAtCarryingValue                                                | \$464.6M   | 2024-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 13 | net income                | us-gaap:NetIncomeLoss                                                                        | \$344.0M   | 2025-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 14 | operating cash flow       | us-gaap:NetCashProvidedByUsedInOperatingActivities                                           | \$564.3M   | 2025-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 15 | assets                    | us-gaap:Assets                                                                               | \$4.7B     | 2024-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 16 | revenue                   | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax                                  | \$4.2B     | 2024-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 17 | cost of revenue           | us-gaap:CostOfGoodsAndServicesSold                                                           | \$3.4B     | 2024-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 18 | revenue                   | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax                                  | \$3.7B     | 2023-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 19 | cost of revenue           | us-gaap:CostOfGoodsAndServicesSold                                                           | \$2.9B     | 2022-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 20 | revenue                   | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax                                  | \$3.0B     | 2022-12-31 | 2025-02-05 | 10-K | 0001125376-25-000021 |
| 21 | cost of revenue           | us-gaap:CostOfGoodsAndServicesSold                                                           | \$2.4B     | 2022-12-31 | 2025-02-05 | 10-K | 0001125376-25-000021 |
| 22 | revenue                   | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax                                  | \$2.6B     | 2021-12-31 | 2024-02-01 | 10-K | 0001125376-24-000018 |
| 23 | cost of revenue           | us-gaap:CostOfGoodsAndServicesSold                                                           | \$2.0B     | 2021-12-31 | 2024-02-01 | 10-K | 0001125376-24-000018 |
| 24 | current assets            | us-gaap:AssetsCurrent                                                                        | \$1.3B     | 2025-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 25 | current liabilities       | us-gaap:LiabilitiesCurrent                                                                   | \$894.3M   | 2025-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 26 | retained earnings         | us-gaap:RetainedEarningsAccumulatedDeficit                                                   | \$1.8B     | 2025-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 27 | liabilities               | us-gaap:Liabilities                                                                          | \$3.2B     | 2025-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 28 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization                                                 | \$104.3M   | 2025-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 29 | operating income          | us-gaap:OperatingIncomeLoss                                                                  | \$255.4M   | 2023-12-31 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 30 | interest expense          | us-gaap:InterestExpense                                                                      | \$8.1M     | 2023-12-31 | 2024-02-01 | 10-K | 0001125376-24-000018 |
| 31 | operating cash flow       | us-gaap:NetCashProvidedByUsedInOperatingActivities                                           | \$192.2M   | 2019-12-31 | 2022-02-09 | 10-K | 0001125376-22-000019 |
| 32 | capital expenditure       | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment                                           | \$71.5M    | 2019-12-31 | 2020-02-05 | 10-K | 0001125376-20-000018 |
| 33 | operating cash flow       | us-gaap:NetCashProvidedByUsedInOperatingActivities                                           | \$210.3M   | 2018-12-31 | 2021-02-03 | 10-K | 0001125376-21-000020 |
| 34 | capital expenditure       | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment                                           | \$50.9M    | 2018-12-31 | 2020-02-05 | 10-K | 0001125376-20-000018 |
| 35 | operating cash flow       | us-gaap:NetCashProvidedByUsedInOperatingActivities                                           | \$79.5M    | 2017-12-31 | 2020-02-05 | 10-K | 0001125376-20-000018 |
| 36 | capital expenditure       | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment                                           | \$54.1M    | 2017-12-31 | 2020-02-05 | 10-K | 0001125376-20-000018 |
| 37 | operating cash flow       | us-gaap:NetCashProvidedByUsedInOperatingActivities                                           | \$73.9M    | 2016-12-31 | 2019-02-06 | 10-K | 0001125376-19-000016 |
| 38 | capital expenditure       | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment                                           | \$65.7M    | 2016-12-31 | 2019-02-06 | 10-K | 0001125376-19-000016 |
| 39 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization                                                 | \$51.1M    | 2019-12-31 | 2022-02-09 | 10-K | 0001125376-22-000019 |
| 40 | operating income          | us-gaap:OperatingIncomeLoss                                                                  | \$129.2M   | 2019-12-31 | 2022-02-09 | 10-K | 0001125376-22-000019 |
| 41 | pretax income             | us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems | \$116.2M   | 2019-12-31 | 2022-02-09 | 10-K | 0001125376-22-000019 |
| 42 | income tax                | us-gaap:IncomeTaxExpenseBenefit                                                              | \$24.0M    | 2019-12-31 | 2022-02-09 | 10-K | 0001125376-22-000019 |
| 43 | current assets            | us-gaap:AssetsCurrent                                                                        | \$411.1M   | 2019-12-31 | 2021-02-03 | 10-K | 0001125376-21-000020 |
| 44 | current liabilities       | us-gaap:LiabilitiesCurrent                                                                   | \$343.2M   | 2019-12-31 | 2021-02-03 | 10-K | 0001125376-21-000020 |
| 45 | current assets            | us-gaap:AssetsCurrent                                                                        | \$348.1M   | 2018-12-31 | 2020-02-05 | 10-K | 0001125376-20-000018 |
| 46 | current liabilities       | us-gaap:LiabilitiesCurrent                                                                   | \$269.2M   | 2018-12-31 | 2020-02-05 | 10-K | 0001125376-20-000018 |
| 47 | assets                    | us-gaap:Assets                                                                               | \$4.2B     | 2023-12-31 | 2025-02-05 | 10-K | 0001125376-25-000021 |
| 48 | assets                    | us-gaap:Assets                                                                               | \$3.5B     | 2022-12-31 | 2024-02-01 | 10-K | 0001125376-24-000018 |
| 49 | shares outstanding        | dei:EntityCommonStockSharesOutstanding                                                       | 58,112,780 | 2026-01-30 | 2026-02-04 | 10-K | 0001125376-26-000007 |
| 50 | shares outstanding        | dei:EntityCommonStockSharesOutstanding                                                       | 57,455,374 | 2025-01-31 | 2025-02-05 | 10-K | 0001125376-25-000021 |